Merck is trading 9.39% up at $148.64 after Merck and Moderna announced positive Phase 3 results for their personalized mRNA melanoma vaccine.
- Combined with Keytruda, the treatment met its primary recurrence-free-survival and secondary distant-metastasis endpoints in more than 1,100 patients.
- Healthcare is up 1.90% as the company-specific oncology catalyst drives sector momentum.
- Reuters and CNBC confirmed the trial success.